Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update

Daix (France), New York (New York, United States), September 28, 2026 — Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohep…